
Cidara Therapeutics (CDTX) P/E Ratio
P/E Ratio as of Jun 16, 2025: -0.77
Average-0.8390
Median-0.8300
Minimum-0.9300
Maximum-0.7500
-0.77
Past Month-0.05 (6.94%)
The P/E ratio for Cidara Therapeutics (CDTX) is -0.77 as of Jun 16, 2025. This represents a increase of 14.93% compared to its 12-month average P/E ratio of -0.67. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Cidara Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Cidara Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Cidara Therapeutics to industry peers.
Cidara Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Cidara Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Cidara Therapeutics to industry peers.
Cidara Therapeutics (CDTX) P/E Ratio Insights
See Cidara Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Cidara Therapeutics (CDTX)
Order type
Buy in
Order amount
Est. shares
0 shares
Cidara Therapeutics (CDTX) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $22.665 | -0.78 |
May 1, 2025 | $21.75 | -0.73 |
Apr 1, 2025 | $18.92 | -0.64 |
Mar 3, 2025 | $23.05 | -0.90 |
Feb 3, 2025 | $18.95 | -0.74 |
Jan 2, 2025 | $27.30 | -1.07 |
Cidara Therapeutics (CDTX) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -0.77 | -26.67% |
2024 | -1.05 | -49.52% |
2023 | -2.08 | +50.72% |
2022 | -1.38 | -9.21% |
2021 | -1.52 | +36.94% |
2020 | -1.11 | — |
FAQs About Cidara Therapeutics (CDTX) P/E ratio
The latest P/E ratio of Cidara Therapeutics (CDTX) is -0.77, as of Jun 16, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Cidara Therapeutics’s last 12-month average P/E ratio is -0.67, compared to its current P/E ratio of -0.77. This reflects a increase of 14.93%.
Cidara Therapeutics’s current P/E ratio of -0.77 is higher than its last 12-month average P/E of -0.67. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Cidara Therapeutics’s average P/E ratio over the last 3 years is -2.4. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Cidara Therapeutics’s average P/E ratio over the last 5 years is -2.06. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.